Scarica l'app Stockscreener
1.90
5.94%
-0.12
Dopo l'orario di chiusura:
1.82
-0.08
-4.21%
Precedente Chiudi:
$2.02
Aprire:
$1.96
Volume 24 ore:
333.98K
Relative Volume:
5.20
Capitalizzazione di mercato:
$12.74M
Reddito:
$2.35M
Utile/perdita netta:
$-2.56M
Rapporto P/E:
-4.2401
EPS:
-0.4481
Flusso di cassa netto:
-
1 W Prestazione:
-11.63%
1M Prestazione:
+0.00%
6M Prestazione:
+1.06%
1 anno Prestazione:
-1.04%
Intervallo 1D:
$1.80
$1.96
Intervallo di 1 settimana:
$1.80
$2.24
Portata 52W:
$1.50
$2.483
Immuron Limited Adr Stock (IMRN) Company Profile
Nome
Immuron Limited Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta IMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.90 | 13.60M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immuron Limited Adr Borsa (IMRN) Ultime notizie
[6-K] Immuron Ltd Current Report (Foreign Issuer) - Stock Titan
Immuron Announces Clinical Trial Update - GlobeNewswire Inc.
Immuron CEO to Present at AusBiotech Invest 2025 Conference - TipRanks
IMRN furnishes 6-K with ASX updates and Exhibit 99.1 - Stock Titan
Immuron Ltd. (ADR) (US45254U1016.SG) Stock Price, News, Quote & History - Yahoo
Immuron Limited Announces 2025 Annual General Meeting - MSN
[6-K] Immuron Ltd Current Report (Foreign Issuer) | IMRN SEC FilingForm 6-K - Stock Titan
Immuron Submits IMM-529 IND to FDA - markets.businessinsider.com
Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment - GuruFocus
Immuron Limited Submits IND Application to FDA for IMM-529 to Combat Clostridioides difficile Infection - Quiver Quantitative
$400M Market Potential: Immuron's C. Difficile Drug IMM-529 Heads to FDA as Company Advances 3 Key Programs - Stock Titan
Immuron Limited Secures Auditor Consent for Financial Filings - MSN
What analysts say about Immuron Limited ANW stockBear Market Strategies & Low Risk Capital Gains - earlytimes.in
Is Immuron Limited Depositary Receipt forming a reversal patternJuly 2025 Earnings & Low Risk Entry Point Guides - newser.com
Is it too late to sell Immuron Limited Depositary ReceiptMarket Activity Report & Fast Moving Trade Plans - Newser
Does Immuron Limited Depositary Receipt fit your quant trading modelJuly 2025 Price Swings & High Win Rate Trade Tips - Newser
Statistical indicators supporting Immuron Limited Depositary Receipt’s strengthPortfolio Risk Summary & Real-Time Sentiment Analysis - Newser
What institutional flow reveals about Immuron Limited Depositary ReceiptEarnings Growth Summary & Entry Point Strategy Guides - Newser
Immuron Limited Depositary Receipt stock trend forecastWeekly Investment Summary & AI Optimized Trading Strategy Guides - Newser
Visualizing Immuron Limited Depositary Receipt stock with heatmapsAI Trading Forecast Based on Big Data - Newser
BNY Mellon Increases Stake in Immuron Limited - TipRanks
Immuron Limited Announces Cessation of Securities - TipRanks
What drives Immuron Limited Depositary Receipt stock priceHigh-yield capital appreciation - jammulinksnews.com
Immuron - GlobeNewswire Inc.
Immuron Crushes Sales Forecast: North America Soars 76%, Global Revenue Breaks Records at $7.3M - Stock Titan
immuron ltd files for quotation of securities on ASX By Investing.com - Investing.com South Africa
immuron ltd files for quotation of securities on ASX - Investing.com
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - BioSpace
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
Immuron Travelan® continued strong sales growth - FinancialContent
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive financial news
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewswire
Immuron requests pre-IND meeting for IMM-529 with FDA filing - FinancialContent
symbol__ Stock Quote Price and Forecast - CNN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com
Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering - Stock Titan
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates - Yahoo Finance
IMC Reports Rising Revenues & Eyes Colitis Market - Next Investors
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
IMC Stock Price and Chart — ASX:IMC - TradingView
Immuron Limited (IMRN) stock price, news, quote and history - Yahoo! Finance UK
Immuron Limited Adr Azioni (IMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):